CRISPR gene editing has moved from Nobel Prize-winning laboratory discovery to approved commercial therapy with CASGEVY — co-developed by Vertex Pharmaceuticals and CRISPR Therapeutics. Approved for sickle cell disease and beta-thalassemia, CASGEVY is priced at $2.2-3.1 million per treatment and represents the commercial validation of gene editing as a therapeutic modality. Base editing and prime editing — next-generation gene editing approaches that modify DNA with greater precision and fewer off-target effects — are advancing through clinical development. In vivo gene editing — delivering editing machinery directly to target tissues without ex vivo cell manipulation — is the next frontier that could dramatically expand the addressable patient population.
Topics Covered
• CRISPR Technology Mechanism
• CASGEVY Commercial Launch
• Base Editing and Prime Editing
• In Vivo Gene Editing
• Intellectual Property Landscape
• Manufacturing of Gene-Edited Cells
• Reimbursement and Access
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. CRISPR Technology Mechanism
4. CASGEVY Commercial Launch
5. Base Editing and Prime Editing
6. In Vivo Gene Editing
7. Intellectual Property Landscape
8. Manufacturing of Gene-Edited Cells
9. Reimbursement and Access
10. Competitive Landscape
11. Competitive Landscape
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. CRISPR Technology Mechanism
Table 3. CASGEVY Commercial Launch
Table 4. Base Editing and Prime Editing
Table 5. In Vivo Gene Editing
Table 6. Intellectual Property Landscape
Table 7. Manufacturing of Gene-Edited Cells
Table 8. Reimbursement and Access
Table 9. Competitive Landscape
Table 10. Leading Companies — Technology Investment and Strategy 2025
Table 11. M&A and Partnership Activity 2023-2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
Spark Therapeutics
BioMarin
Sarepta
bluebird bio
Ultragenyx
Novartis Gene Therapies
Regenxbio
